Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2023.296 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK‑0616 in Adults With Heterozygous Familial Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.449 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.409 | Validation of Pulse Sensors for Cardiovascular Disease Management |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2022.335 | Evaluation of the Relationship Between Arterial Stiffness and Coronary Artery Disease by Stroke-Volume-Allocation |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.457 | Develop multi-modal spectroscopy (MMS) & biosensor platforms for monitoring cardiovascular diseases (CVDs) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.316 | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR™ 018 Drug Eluting Balloon in the Treatment of Subjects With Femoropopliteal Artery Lesions |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.637 | Drug-Coated Balloon for the Treatment of De Novo and Restenotic Coronary Artery Lesion: a prospective observational study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.577 | Switching Sildenafil to Riociguat in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) | Prof. YAN Bryan Ping Yen |
| 2022.038 | Prevalence of LVEF non-recovery after acute myocardial Infarction |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.186 | Investigation of the adverse effects of antiviral compounds |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.065 | Real World Effectiveness of Evolocumab among Chinese Patients in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2023.041 | A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2023.194 | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.502 | Development of Fluorescence Probes and Nanomaterial for Plaque and Thrombosis Imaging in Patients | Prof. YAN Bryan Ping Yen |
| 2023.362 | A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.287 | Validation of a novel device for screening patients with atrial fibrillation / arrhythmia | Prof. YAN Bryan Ping Yen |
| 2022.501 | The effect of early inpatient initiation of Dapagliflozin on the Health-related Quality of Life of patients with heart failure with all range of Ejection Fraction: a Local Registry | Prof. YAN Bryan Ping Yen |
| 2022.497 | In-hospital initiation of Angiotensin–Neprilysin Inhibition for the treatment of acute heart failure regardless of ejection fraction: An open labelled randomized study | Prof. YAN Bryan Ping Yen |
| 2014.332 | A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting. (RE-DUAL PCI) | Prof. YAN Bryan Ping Yen |
| 2012.481 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome | Prof. YAN Bryan Ping Yen |
| 2011.178 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Prof. YAN Bryan Ping Yen |
| 2013.420 | Transcatheter Renal Denervation with an over-the-wire balloon based technology for Patiemts with Resistant Hypertension | Prof. YAN Bryan Ping Yen |
| 2014.210 | Randomized controlled trial and cost-effectiveness analysis of targeted rapid screening for atrial fibrillation using a handheld single-lead ECG device with automated diagnostics and tailored stroke prevention strategy for screen-detected patients | Prof. YAN Bryan Ping Yen |
| 2012.561 | Novel Treatment of Intermittent Claudication in Patients with Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule | Prof. YAN Bryan Ping Yen |
| 2013.658 | A PHASE 3 DOUNLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDMIA AT RISK OF CARDIOVASCULAR EVENTS | Prof. YAN Bryan Ping Yen |
| 2013.586 | GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III) | Prof. YAN Bryan Ping Yen |
| 2024.156 | A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.212 | Retrospective Database Study for Treatment Patterns of Lipid-lowering Therapy in Patients with Hypercholesterolemia or Mixed Dyslipidemia in Hong Kong, South Korea, and Taiwan (READY Study) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.339 | Investigations of cardiotoxicity in cancer survivors | Prof. YAN Bryan Ping Yen |
| 2024.152 | Rationale and design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.468 | AI-Based Intima-Media Thickness Measurement for Cardiovascular Risk Assessment |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.251 | BIOTRONIK – Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (Freesolve) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A randomized controlled trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.296 | International Survey on Current Status & Future of Drug-Eluting Stents |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.456 | Diagnostic Accuracy and Incremental Prognostic Value of Exercise MCG in Patients at Risk of Coronary Artery Disease |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2014.380 | A pilot study to assess efficacy and safety of a novel Titanium-Nitride coated woven-nitinol Peripheral Arterial Stent | Prof. YAN Bryan Ping Yen |
| 2016.623 | Pharmacoepidemiology and pharmacoeconomics of oral anticoagulation therapy in Hong Kong | Dr. YAN Bryan Ping Yen |
| 2017.366 | ACCelerated ThrombolySiS for Post-Thrombotic Syndrome Using the EKOS System |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.302 | ASTRI Wireless ECG Module Public Trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2014.258 | A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo | Prof. YAN Bryan Ping Yen |
| 2016.509 | Hong Kong Percutaneous Coronary Intervention Registry |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.531 | Prospective Observational study of Lipid Management in Non-US, Non-Western European Patients Who Have A Recent Acute Coronary Syndrome Event |
Dr. YAN Bryan Ping Yen 甄秉言 |
| 2015.292 | A novel non-invasive radial artery tonometric cardiovascular monitoring device for assessment of vascular aging, subclinical atherosclerosis and cardiovascular risk in the elderly. |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.638 | Defining the athletes heart phenotype: A comparison of male Caucasian and East Asian elite footballers and rugby players |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.490 | Development of personalized medicine using Prenetics iGenes pharmacogenomic panel to predict individual responses to cardiovascular drugs |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.297 | Optical Coherence Tomography evaluation of Very Early eNdothelialization after Dual Therapy Drug-eluting Stent with EPC CaptURE (OCT-VENTURE) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2015.291 | Optimal Bioabsorbable Vascular Scaffold Technique for Complex Bifurcation Lesions |
Dr. YAN Bryan Ping Yen 甄秉言 |
| 2016.550 | Validation of Camera-based Measurement of Finger & Facial Photoplethysmographic Signal for Heart Rate and Arrhythmias Detection |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2017.358 | Optical Coherence Tomography evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris | Prof. YAN Bryan Ping Yen |
| 2015.301 | Effects of Cardiovascular Autonomic Nervous System Activities on BP/ECG/PPG/Respiratory Related Physiological Features, Validation of Improved PTT-based Cuffless BP Estimation with IEEE 1708 Standard, and Measurement of Respiratory Rate with a Novel Method |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2016.630 | Renal Artery Sympathetic Denervation by Catheter Ablation after Pulmonary Vein Isolation (PVI) for Persistent Atrial Fibrillation |
Prof. YAN Bryan Ping Yen 甄秉言 |
Page 17 of 262.